trial

A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

NCTId NCT01529515
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 509 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2014-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
509 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2012-05
Primary completion
2014-04
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
PP3M 175 mg eq.PP3M 263 mg eq.PP3M 350 mg eq.PP3M 525 mg eq.

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

0 total

Linked catalysts

1
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patie — primary completion2014-04

Facts & assertions

4 sourced
Enrollment
509
Phase
PHASE3
Primary Completion Date
2014-04
Status
COMPLETED
relationships
The graph out of here
drug
PP3M 175 mg eq.
drug
PP3M 263 mg eq.
drug
PP3M 350 mg eq.
drug
PP3M 525 mg eq.
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication